• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Benzopyrans represented by the formula …<CHEM>… wherein A represents a direct bond or -CH2O-… R1 represents a C3-C5 alkyl group, a hydroxy-(C3-C5 alkyl) group, a lower alkyl-amino-lower alkyl group, a nitrato-(C3-C5 alkyl) group or a phenyl-(C1-C5) alkyl group where the phenyl may be substituted by a lower alkoxy group, R2 represents hydrogen, halogen, OH, NO2, a carbamoyl group, a lower alkyl group, a lower alkoxy group, a lower alkyleneoxy group or an acetyl group, R3 represents hydrogen or NO2, B represents a direct bond, a C1-C7 alkylene group, a -O-lower alkylene group or a -CONH- lower alkylene group, and… n represents 1 or 2; and their acid addition salts are useful, for example, in reducing heart beat rate, myocardial oxygen consumption and blood pressure.
    公开号:SU1212325A3
    申请号:SU813300799
    申请日:1981-06-16
    公开日:1986-02-15
    发明作者:Сиратсути Масами；Симизу Нобору；Сигие Хиромити；Киотани Есинори；Куниеда Хисаси；Кавамура Киеси；Сато Сейити；Акаси Тосихиро；Нагакура Масахико；Савада Наотоси；Утида Ясуми
    申请人:Коува Компани,Лтд (Фирма)；
    IPC主号:
    专利说明:

    I
    The invention relates to a method for producing new benzopyran derivatives of the formula
    .C-CH-H2C
    sh
    (Jj
    where R, - C-CiHy and L are B-direct or (.-alkylene, which have different pharmacological activities, I aKHMH as a relaxing effect on smooth muscles, rich in blood vessels, adrenergic N-blocking; its an action that results in a decrease in heart contractions, a decrease in the effect on myocardial oxygen consumption, an increase in the current: a blood effect, and a decrease in the blood pressure level.
    The aim of the invention is to obtain new benzopyr derivatives for formulas (I) having; stronger and blocking action.
    Example 1 3.4 Dihydro-8 G (2 hydroxy 3-isopropylamino) -prop-hydroxy-3-nitrate 8-ethyl-2P 1 -benzopirane (b).
    Dissolve 23: 95 g of 3A-dihydro-8 oxo 3-hydroxymethyl 2H-1-benzopyran in 270 ml of tetrag.ydrofuran, and 14.8 g of triztkl-1-shn are added to the mixture. The mixture is cooled on ice with stirring and added dropwise. m solution. 9.5 g of ethyl chloroformate in 135 tetrahydrofuran for 1.5 hours. After the reaction, the insolutes are filtered off, the 1st and 1 st substances are dispersed and the mother liquor is removed under reduced pressure, 50 m islladatetate is added to the residue to form a thief. The solution is successively diluted with 2n. hydrochloric acid and saturated aqueous solution: sodium aorist and dried. The solvent is distilled off, 33e6 g (100% yield) of 3.4 dihydro-8-ethoxycaroneyl-3 3 UXYmethyl-2H-1-benzopyrano are obtained.
    This product is dissolved in 320 ml of acetonitrile and a solution consisting of 3 grams of nitric acid smoke, g of acetic anhydride and 75 ml of acetonitrile is added dropwise with stirring with cooling, in three portions at 10 -1-minute intervals. Mixture of interlaced a-
    101 e; just 10 min. After the reaction, add sodium bicarbonate aqueous solution to adjust the pH of the reaction mixture to 7.0, and then extract the mixture with 50 ml of ethyl acetate. The extract is washed with a saturated aqueous solution of hydrosporous sodium and distilled off the plant; 39.7 g (yield 100%) of 3 5 4 -dihydro-8-ethoxycarbonyloxy-3-pitratomethyl-2H -1-benzopyran, NMR: S (CDCl): 3.9O-4, y (6H, m, CH2O2 / -COOCH2 CH2),
    n
    6, (ZN, m, aromatic H). IR:) liquid film, cm: 1770
    (), 1630 (-NO).
    39.7 g of the obtained 3 5 4 dihydro-8 ethoxycarbonyloxy-3-nitratomethyl 2H-1-benzopyran are dissolved in
    280 g-w of methanol and add 160 ml of 1N. sodium hydroxide solution. The mixture is stirred at room temperature for 20 minutes. After the reaction, 2N was added. hydrochloric acid to adjust the pH of the reaction mixture jjO. The solvent is distilled off at the same pressure. The residue is extracted with 500 ml of ethyl acetate. The extract is sprayed with a saturated aqueous solution of sodium chloride and then the solvent is distilled off under reduced pressure5 to obtain 27.6 g of a black-brown viscous oil. The oil is purified on a chromatographic column with silica gel. 18 g (yield: 60.3%) of 3.4-dihydro-8-hydroxy-3 nitrate of GIL-2H -1-benzopyran are obtained.
    The compound was dissolved in 240 ml of dioxap and 80.15 ml was added. 1N. solution of sodium hydroxide and 32.2 ml of zpkhlorh idrina. The mixture is reacted at 50 ° C for 2 hours. After the reaction, 500 ml of chloroform is added and the mixture is washed
    an aqueous solution of sodium chloride and sutaat. The solvent was distilled off under reduced pressure, yielding 22.5 g} of a brown viscous oil. The oil is purified on a chromatographic
    on silica gel, 16.35 g (72.5% yield) 3.4 Dihydro-8 (2.5-epoxy) - nponoKcnl -3 nitromethene-3 is obtained.
    i
    2H-1-benzopyran. NMR: (CDCl):
    / - ° N 2.28-3.10 (5H; m, -CHj-CH-CH
    3.25-3.57 (IH, m, CHi-CH-CHz
    3.92-4.38 (4H, 4.52 (2H, d, J
    mf CH 2
    6 Hz, 6.63-6.95 (ZN, m, arom
    11.35 g of the obtained
    3,4-dihydro-8- (2,3-epoxy) -propoxy-3-nitrotomethyl-2H-1-benzopyran in 570 ml of ethanol and 144 m of isopropylamine added. The mixture is reacted at reflux for 30 minutes with stirring. After the reaction, the solvent was distilled off under reduced pressure to obtain 15.0 g of a light brown viscous oil. The oil is purified on a chromatographic column with alumina oxide to give 8.55 g (yield: 62.3% of 3,4-dihydro-8-f (2-hydroxy-3-isopropyl-amino) -propoxyT-3-nitratomethyl-2H - -1-benzopyran in the form of colorless needles with mp 64-68 C.
    Calculated,%: With 56.46; H 7.11;


    N 8.23,
    (
    Found,%: C 56.76; H
    N 8.17.
    HMP: g (CDCl,): 1.08 (6H, d
    -sn,
    -sn
    N
    CH,
    4.50 (2H, d, J 6 Hz, -CH2nN02) 6,, 93 (3N, m, aromatic H), IR: -5 kWg (): 1620, 1270 (NO). Maleate salt: colorless needles, so pl. P4-116 ° C.
    Example 2. 3,4-Dihydro-8- (2-hydroxy-3-isopropylamino) -propoxy-3-nitrato-2H-I-benzopyran (1a).
    23.05 g of 3,4-digidro-3,8-dioxy-2H-I-benzopyran is dissolved in 320 ml of tetrahydrofuran and 16.7 g of triethylamine are added. With stirring and cooling, a solution of 17.9 g of ethyl chloroformate in 100 ml of tetrahydrofuran is added dropwise. The mixture was worked up as described in Example I, 33.1 g (100% yield) of 3,4-di-hydro-8-ethoxycarbonyloxy-3-hydroxy-2H-1-benzofuran were obtained.
    34.0 g of the obtained compound is dissolved in 600 ml of acetonitrile and the solution is cooled. With stirring, the solution is added,
    / - ° N H-CH
    H-CHz
    H
     2 9
    15
    CHjONO) ical H).
    ten

    Y
    SOH
    n n
    O./and n

    20
    25
    thirty
    From 24.1 g of fumed nitric acid, 38.3 g of acetic anhydride and 66 ml of acetrile, the reaction conditions and purification are the same as in Example 1, 10.95 g are obtained (yield 27.1%) 3.4- -dihydro-8-ethoxycarbonyloxy-3-nitrato-2H-1-benzopyran. This compound is hydrolyzed in the usual manner and 7.65 g (yield: 96.3%) of 3,4-dihydro-8-hydroxy-3-nitrato-2H-I-benzopyran are obtained in the form of light yellow prisms.
    7.30 g of the obtained compound is dissolved in 41.5 ml of I. n. sodium hydroxide solution and 6.72 g of epichlpridhydrin is added. The mixture is stirred at room temperature P h and then is treated according to the method of Example 1, 4.80 g (yield: 52.0%) of 3,4-DIHIDRO-8- (2,3-β-epoxy) -propoxy-3-nitrate is obtained. 2H-1-benzopyran in the form of colorless crystals. NMR: B (CDCl1): 2,. O. 3.63 (5H, m, -OCHj
    35
    40
     3.97-4.27 (2H, m
    5.27-5.63 (1H,
    6.57-7.00 (ЗН, m,
     Y-CH-CH-y 1 I
    H N
    -axi2-SI-SI)
     O / 2
    ONO-z
    aromatic H).
    3.5 g of the epoxy compound obtained are dissolved in 280 ml of ethanol and 35 ml of isopropylamine are added. The mixture is stirred at reflux for 30 minutes. After the reaction, the solvent was distilled off under reduced pressure. The residue obtained is purified on a silica gel chromatography column, to obtain 3.42 g (yield: 80.0%) of 3,4-dihydro-8- (2-hydroxy-3-isopropyl-amino) Propoxy-3-nitrato-2H- 1-benzopyran in the form of colorless needles, having so pl. 107-116 ° C.
    Calculated,%: C 55.21; H 6.79; N 8.38.
    Found,%: C 55.10; H 6.80;
    N 8.47,
    NMR: S (CBC1): i, 08 (6H, d,
     6 Hz, sn
    .СНз
    ai
    about
    5.30-5.63 (H, m, I
    H
    6.63-7.00 (ЗН, m, aromatic Н). (CM-): 1618, 1280 (N0 ,,)
    /
    Compounds (I) have various pharmacological activities, including a relaxing effect on a rich vessel No. 1 smooth muscle, adrenergic - and blocking effect resulting in a decrease in the rate of heartbeats, a decrease in myacardial oxygen consumption, an increase in - blood flow and reduction in blood pressure. Because of the presence of these pharmacological activities, these compounds may be useful as agents for the treatment of cardiovascular diseases, such as anti-angina drugs, antihypertensive agents, drugs for improving cardiovascular dysplasia and antiarrhythmic drugs. on.
    An agent for the treatment of cardiovascular diseases, with the listed pharmacological activities, is not known to date. In addition, the unique pharmacological activities of the compound of formula (I) are long lasting and the absorption of this compound in vivo when administered orally is excellent. The compounds have some toxicity. Consequently} such a pharmaceutical composition is useful for the prevention and treatment of diseases of the cardiovascular system.
    The compound may be in the form of its acid addition salt. The acid addition salt can be easily prepared by contacting the compound of formula (l) with a suitable inorganic or organic acid. Pharmaceutically acceptable acid addition salts are preferred. Examples of acid addition salts are hydrochloric acid salts, nitrates, sulfates, phosphates, oxalates, maleates, methanesulfonates, ethanesulfonates, t-toluene sulfopates, fumarates, lactates, malonates and acetates.
    Liquid or solid carriers or diluents can be used in the preparation of the proposed pharmaceutical devic composition. They can
    include excipients that bind,
    lubricants, emulsifiers, etc. Examples of such carriers or diluents are starch, such as potato starch, wheat starch,
    corn starch and rice starch; al; sugars such as lactose, sucrose, glucose, mannitol and sorbitol; celluloses, such as crista, stiff cellulose, calcium carboxymethyl 1, low substitution grade ylulose and hydroxypropyl cellulose; inorganic substances such as potassium phosphate, calcium sulphate, capon carbonate and talc; binding connecting-
    neither 5 such as gelatin, gum arabic, methylcellulose, sodium carboxymethylcellulose polyvinylpyrrolidone, hydroxypropylcellulose; esters of polyatomic alcohols such as non-ionic
    surface-active substances, such as monogly1, ers of hydrochloric acids, esters of fatty acid and sorbitol, esters of sucrose and polyglyceric fatty acid, and polyoxyethylene-type ionic substances.
    Pharmaceutical compositions can be in any form of a dose, such as suppositories, powders, granules, tablets,
    sublingual tablets, liquid preparations, preparations for injections and suspensions.
    Pharmaceutical compositions may be administered by any route of oral administration.
    but or parenterally, for example, intravenously, sublingually or intrarectally. For long-term administration, the oral route is preferred.
    Dosage can be changed as desired. For example, a compound of formula (t) may be administered at a dose of from about 1 to 100 mg / kg of body /
    / day, preferably about 5-50 mg / kg body / day. The proposed compounds have very low toxicity, which indicates that their acute toxicity (LDy) is 500-1000 mg / kg (mouse, oral) and 65-100 mg / kg (mouse, intravenously).
    The following are examples of testing the pharmacological efficacy of compounds of formula (I).
    The following experimental examples show the effect of compounds of the formula (t) on blood pressure and heart rate.
    Use the following test medications:
    Compound 1a: Z.A.-dihydro-8L (2-hydroxy-3-isopropylamino) -propoxy) -3-nitrato-2H-benzopyran;
    Compound 16: 3,4-dihydro-8- - L (2-hydroxy-3-isopropylamino) -prop-oxy1-3-nitratomethyl-2H-benzopyran. Comparative drug G: propanolol sulphate. Comparative medicine G1: trichloromethiazide.
    Example 3. 1. The effect of the test compound on blood pressure and heart rate was investigated using spontaneously hypertensive rats (CGS), renally hypertensive rats and DOSA hypertensive rats. Arterial blood pressure is measured using a pressure sensor in the femoral artery. The rate of heart contraction is measured by a pressure pulsator by means of a pressure pulsator. The food from the is- (the test compounds are suspended in a 0.5% solution of carboxymethylcellulose and administered orally. The results show the effect of the tested drugs on blood pressure and the rate of heart contraction in spontaneously hypertensive rats, renal hypertensive rats and DOSA -hypertensive rats, respectively: injected,., Compound 1a at a dose of 3 mg / kg; Compound 1a was administered at a dose of 10 mg / K Compound GB was administered at a dose of 3 mg / kg Compound 16 was administered in a dose 10 mg / kg; comparative drug is administered
    I at a dose of 10 mg / kg; and comparative drug T is administered at a dose of 30 mg / kg.
    The results show that the compounds Ta and 1b quickly manifest their effect upon oral administration and their activity remains for a long period of time. Therefore, in contrast to the well-known antihypertonic drugs, compounds 1a and 16 do not cause a reflex increase in the rate of contraction of the heart in the event of a drop in blood pressure and therefore are extremely safe. Consequently, the properties of these compounds differ from traditional β-blocking drugs in that compounds 1a and 16 reduce both systolic and diastolic blood pressure to the same extent.
    2. Compound 1a was administered orally at a dose of 3 or 10 mg / kg to spontaneously hypertensive rats for 4 weeks and the blood pressure and weight of the rats were measured.
    Compound la was administered at a dose of 3 mg / kg, and then at a dose of 10 mg / kg.
    The results show that even when the proposed compound is administered over a wide period of time, its antihypertensive effect is preserved, inhibiting the progression of hypertension. Its long-term safety is confirmed by the fact that compound 1a and 16 does not cause an increase in body weight.
    Example 2. Experimental.
    Five rats were used per group, the amount of urine and the amount of electrolytes (sodium, potassium) were measured, 5 hours after oral administration of drugs by the method of oral loading with water. Each of the tested drugs is suspended in a 0.5% solution of carboxymethylcellulose and administered orally. The results are shown in Table. 1. Each of the numerical values shown in the table is the average value of t standard deviation.
    s

    thirty
    ten
    thirty
    22,511.4 27.8t3.7
    24.25: 2.2
    3i, ± 3.2
    19.4i4.0
    thirty
    thirty
    34.8 ± I, 7
    32,6i4,5
    100 34, Q ± 3.7
    The results show that the Compounds have marked diuretic and electrolyte-releasing activities.
    Example 3. Experimental. Adult dogs were anaesthetized with 30 mg / kg of pentobarbital administered intravenously and kept on artificial respiration. The effect of compounds 1a and 16 on hemodynamic parameters was studied. Drugs used dissolved in 0.1 n. hydrochloric acid and was administered in the dose range from 1 to 300 µg / kg.
    1. The mean blood pressure (ACS) is measured in a cannulated femur artery with a pressure transducer. laziness.
    2. The rate of cardiac contraction (SSS) is measured by a cardiotachometer, which is started during the ECG.
    3. The cardiac capacity (CE) is measured by an electromagnet flow meter placed in the ascending aorta.
    3.0810.27 0.53 ± 0, i5 0.18 J: 0.04
    3.42tO, 28 0.7010.11 0,, 04
    3.251-0.18 0.6110.20 0.19 ± 0.07
    4.1810.56 0.91iO, 23 0,, 05 2.76iO, 83 0.55tO, l4 0,, 08
    5.36iO, 42 1.1210.18 0.21 + 0.04
    3.87tO .64 0.8310.36 0, 08
    3.69 + 0.33 0.14 ± 0.45 0.3010.10
    4. The diastolic pressure at the end of the left ventricle (DUHYO) is measured by a catheter sensor with a micro-tip inserted into the left ventricle.
    5. Coronary blood flow, measured by an electromagnetic flowmeter: placed in the left envelope of the branch.
    6. General carotid artery blood flow. Measured by electromagnetic.
    flowmeter placed in the common carotid artery.
    7. Renal blood flow is measured by an electromagnetic flowmeter.
    placed in the left renal artery.
    8. The femoral blood flow is measured by an electromagnetic flow meter inserted into the Lemoral Artery.
    Connected-and 1a and 16 show a prolonged hypotensive aftereffect at low doses (3-30 microns / kg) and a clear transitional hypotensive
    l
    action, and then a long hypotensive after-effect at high doses. At doses of 1–3 µg / kg, the proposed compounds begin to show prolonged aftereffect at high doses. At doses of 1–3 µg / kg, the compounds begin to show a prolonged after-effect to reduce the rate of heart contractions. At low doses, they show a deist to a decrease in cardiac capacity, and at high doses, a transient effect on an increase and then on its decrease. They also show a transient reducing effect on total peripheral resistance at doses of 10–30 µg / kg. At high doses, they act to reduce diastolic pressure at the outlet of the left ventricle, and at low doses, they have the effect of reducing the maximum rate of contraction of the left ventricle.
    The results of tests 5-8 are shown in Table. 2 (+: intermittent increase of 5–20%; ++: intermittent increase of 20–50%; -: a steady decrease of).
    Table 2
    5. Coronary blood flow
    6. The total flow of the carotid artery
    7. Renal blood flow
    8. Femoral
    blood flow
    An increase of about 10% at low doses and a decrease of about 20% at high doses.
    After injection, the coronary blood flow shows an intermittent increase and then a continuous decrease. This intermittently increasing effect is due to the vasodilataticular effect of the compounds.
    0
    R
    five
    325
    la and 16, and the subsequent decrease arises due to a decrease in cardiac work in the case of a decrease in the rate of heart contractions. This is also evident from the fact that the resistance of the coronary vessels continuously decreases. Consequently, the compounds Ha and 16 have different pharmacological activities as compared with traditional 3-blockers, in particular, they have an activity to reduce the resistance of the coronary vessels.
    Blood flow in total carotid
    The 5 arteries, the posterior artery and the renal artery also show the same changes as the coronary blood flow. The transition does not show any increase in their activity.
    0 gift of vasodilating activity. A subsequent decrease occurs due to a decrease in the capacity of the heart, and the resistance of the blood vessels remains below or diminished. The difference is that traditional p-blockers increase the resistance of blood vessels after administration.
    Example 4. The activity of compounds Ha and 16 on various isolated smooth fluids by the Magnus method was investigated. Each of the tested drugs was used in a concentration of from 10 to 4 4 mol / 1000 ml / M /.
    five . Isolated atrial specimens.
    Use the left atrium and the right atrium of the guinea pig, record the contracted strength and rhythm and examine the antagonistic effect of the tested drugs on isoproterenol,
    2. Molded bronchus sample. Use guinea pig bronchi
    investigate the antagonistic effect of the tested drugs on isosproterol.
    3.Isolated coronary artery.
    Use the left envelope of the dog, examine the effect of the tested drugs on the potassium contract - RU.
    4.Isolated gate vein. 5 Use an isolated dog's collar vein, examine the effect of the tested drugs on potassium contracture.
    0
    0
    five
    0
    13
    5, Isolated vein hidden. Use isolated hidden
    A dog's vein is examined for the effects of tested drugs on potassium contraction.
    6.Isolated mesenteric artery.
    The dog's isolated labial artery is used, the antagonistic effect of the tested drugs on (a) potassium contracture and (b) norepinephirine is investigated.
    23251
    The results are presented in table 3. The numbers in the table are the corresponding logarithms of molar concentrations, pA shows the molar concentration of the test drug that is required to shift the dose-response curve of isoproterenol, and the like. parallel to a higher dose in two times; and the PD shows the molar 10 concentration of the test drug, which is required to inhibit the maximum of the potassium reaction by 50%. Table 3
    The results show that the compound of Ha of the invention has strong p- and oi-blocking actinities.
    Example 5. Dosage formulation Tablets, h:
    Compound
    Formula I 6
    Crystalline Cellulose 50
    Lactose 34
    Calcium carboxymethylcellulose9
    Magnesium Stearate 1
    Mix the above ingredients thoroughly and tablet into tablets having a diameter of 5 mm and a weight of 50 mg by the direct tablet method. These tablets have a hardness of 6 kg and a disintegration time of 1 min.
    Example 6. Dosage Formulation.
    35
    40
    45
    Pellets, h: Compound of formula L Crystalline cellulose
    Lactose Cornstarch Oxypropyl-cellulose Ethanol
    Ingredients A are evenly mixed, then kneaded with solution B. The mixture is granulated by an extrusion-granulation method, then shat under vacuum and sieved,
    Example 7. Dosage formulation.
    Fine Particles: Compound of formula I2 Crystalline cellulose 20
    Lactose 50
    White sugar 26
    Hydroxypropylcellulose 2
    Mix the above ingredients evenly and knead ethanol for 25 hours. The mixture is granulated by a pulping-granulating method, dried in a stream of air at 50 ° C and sieved.
    Example recipe.
    Capsules, h:
    Compound
    formulas i
    Lactose
    Crystalline Cellulose 30
    Talc10
    The ingredients are mixed evenly and 90 mg of the mixture is packed in each capsule No. 5,
    A comparison of the pharmacological activity of the control drug (this compound is closer in its properties to compounds 1a and 1b, that is, the control drug G1) and compounds 1a and 16 are shown in the following table 4.
    8, Medicinal
    ten
    40
    Table 4
    five
    0
    five
    | 3-blocking action in relation to the allocation of adrenaline-like substances
    Lower blood pressure
    Reduced heart rate Effect on diastolic pressure in the left ventricle Effect on blood circulation through the carotid artery
    Tales-Renders
    Lower-No-lower
    yutet
    Reduce
    Reduces
    Reduces - Increases Enhance - Do not curb;
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING BENZOPYRANE DERIVATIVES of the general formula
    SnH 2 C-CH-H2C-Q * he where R | - SS f -alkyl; B is a direct alkylene bond, a compound of the formula n 2 s — he — H 2 C. o b-oio 2> or C * —C 4 * i in that, ono 2 where B has the indicated meanings, * are reacted with an amine of the formula
    NH 2 R f , where R * has the indicated meanings, in an alcohol environment at the boiling point of the reaction medium.
    12’2325
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1212325A3|1986-02-15|Method of producing derivatives of benzopyran
    US4923874A|1990-05-08|Use of 8-azapurin-6-one derivatives for control of hypertension
    US8017786B2|2011-09-13|Substituted β-phenyl-α-hydroxy-propanoic acid, synthesis method and use thereof
    US4161595A|1979-07-17|Levulinic acid salt
    EP0705244A1|1996-04-10|Nitrato amino acid disulphides for use in the therapy of disorders of the cardiovasculary system
    SU1470190A3|1989-03-30|Method of producing 6-/4ъ-acetyl-2-methylimidazol-1-yl/-8-methyl-2-|-carbostyrene
    SU1082317A3|1984-03-23|Process for preparing derivatives of aminopropanol or their salts
    EP0178261A2|1986-04-16|Substituted 2-furanyl or 5-oxo-2-furanyl-alkoxy phosphoryl alkyl cyclimmonium salts
    EP0010120A1|1980-04-30|1-|-4-dialkoxyphosphinyl methylbenzene derivatives and pharmaceutical compositions containing them
    US4035366A|1977-07-12|1-Benzal-1,2,3,4-tetrahydro-isoquinolinium-theophylline-7-acetates
    DK171782B1|1997-05-26|Use of 3,4-dihydro-2H-benzo [b] pyrans for the manufacture of a drug against obstructive pulmonary dysfunction
    US4600710A|1986-07-15|β-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives
    CS239935B2|1986-01-16|Precessing of substituted ncarboxyamidealkyl-fenoxypropan amine
    EP0266504A2|1988-05-11|Use of N6-[| methyl]-adenosine in the preparation of pharmaceutical compounds for treating congestive heart failure
    US4156739A|1979-05-29|Anti-hypertensive compounds
    HU188061B|1986-03-28|Process for the preparation of benzopyrane derivatives and pharmaceutical compositions containing said compounds as active ingredients
    US4980351A|1990-12-25|3-aminopropoxyaryl derivatives having cardiotonic and antihypertensive use and compositions thereof
    US4438115A|1984-03-20|Compositions and methods for treating diseases in circulatory organs
    US3968129A|1976-07-06|Azidophenol amine compounds and therapeutic compositions
    SU1082323A3|1984-03-23|Process for preparing naphtidrofuryl citrate
    HU201922B|1991-01-28|Process for producing 1,5-benzoxathiepin derivatives and pharmaceutical compositions comprising same
    JP3049284B2|2000-06-05|Hydantoin derivatives and preventive and therapeutic agents for diabetic complications and cardiovascular diseases using the same as active ingredients
    CS221847B2|1983-04-29|Method of making the ethaloamine derivatives
    EP0106816A2|1984-04-25|Alkanolaminoxy derivatives of 3,4-dihydro-2H-1,4-benzothiazin-3-one, their production process, and their pharmaceutical use
    US3974164A|1976-08-10|Reserpic acid derivatives
    同族专利:
    公开号 | 公开日
    KR850000193B1|1985-03-05|
    DD160453A5|1983-08-03|
    IE811312L|1981-12-17|
    PL130537B1|1984-08-31|
    NO154495B|1986-06-23|
    FI79307B|1989-08-31|
    ZA814042B|1982-06-30|
    EP0042299B1|1984-09-26|
    CS226731B2|1984-04-16|
    AU7165281A|1981-12-24|
    NO812042L|1981-12-18|
    FI811856L|1981-12-18|
    CA1178598A|1984-11-27|
    IE52067B1|1987-06-10|
    DK154557C|1989-04-17|
    ES8300104A1|1982-10-01|
    FI79307C|1989-12-11|
    DK264181A|1981-12-18|
    PL231734A1|1982-08-16|
    ES503091A0|1982-10-01|
    NO154495C|1986-10-01|
    DK154557B|1988-11-28|
    US4394382A|1983-07-19|
    KR830006268A|1983-09-20|
    AU543347B2|1985-04-18|
    DE3166300D1|1984-10-31|
    EP0042299A1|1981-12-23|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    RU2654855C2|2012-12-28|2018-05-23|Аскат Инк.|Salts and crystalline forms|GB1493998A|1975-06-03|1977-12-07|Beecham Group Ltd|Propanolamine derivatives|
    JPS54106476A|1978-01-04|1979-08-21|Merck & Co Inc|Multiisubstituted 2233lower alkylaminoo22 r100propoxypyridine|
    DE2804625A1|1978-02-03|1979-08-09|Thomae Gmbh Dr K|4-Acylamino-phenyl-ethanolamine derivs. - with analgesic, spasmolytic, beta-mimetic and/or beta-blocking activity|
    DE2805404A1|1978-02-09|1979-08-16|Merck Patent Gmbh|1-ARYLOXY-3-NITRATOALKYLAMINO-2-PROPANOLS AND METHOD FOR THE PRODUCTION THEREOF|JPH0227987B2|1982-10-05|1990-06-20|Kowa Co|
    JPS60181083A|1984-02-29|1985-09-14|Kowa Co|Novel racemic compound and its conversion|
    JPH0422887B2|1984-03-31|1992-04-20|Kowa Co|
    GB8730051D0|1987-12-23|1988-02-03|Beecham Group Plc|Novel compounds|
    AU727416C|1996-05-14|2001-07-19|Glaxo Group Limited|Benzofurans and benzopyrans as chronobiological agents|
    TWI290470B|1999-12-01|2007-12-01|Sankyo Co|The composition for treating glaucoma|
    DE60336485D1|2002-08-19|2011-05-05|Pfizer|COMBINATION THERAPY AGAINST HYPERPROLIFERATIVE DISEASES|
    AU2003275609A1|2002-10-24|2004-05-13|Kowa Co., Ltd.|Nerve fiber regeneration accelerator|
    US20050037063A1|2003-07-21|2005-02-17|Bolton Anthony E.|Combined therapies|
    GT200600381A|2005-08-25|2007-03-28|ORGANIC COMPOUNDS|
    US7741317B2|2005-10-21|2010-06-22|Bristol-Myers Squibb Company|LXR modulators|
    US7888376B2|2005-11-23|2011-02-15|Bristol-Myers Squibb Company|Heterocyclic CETP inhibitors|
    WO2008070496A2|2006-12-01|2008-06-12|Bristol-Myers Squibb Company|N--2, 2--propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases|
    CA2909442A1|2013-04-17|2014-10-23|Pfizer Inc.|N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases|
    WO2016055901A1|2014-10-08|2016-04-14|Pfizer Inc.|Substituted amide compounds|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP8084180A|JPS6054317B2|1980-06-17|1980-06-17|
    JP55182854A|JPH0153245B2|1980-12-25|1980-12-25|
    [返回顶部]